



DAICEL CORPORATION



<u>Index</u>

1. Highlights	P. 3
2. Business Environment	P. 4
3. Consolidated Financial Results	P. 5
4. Forecasts	P. 11
5. Shareholders Return	P. 15
6. Towards Achievement of Mid-Term Management Strategy	P. 16
7. References	P. 20





Highlights

♦ 2022/3 1H Financial Results

- Sales Revenue: 224.8 billion yen, Operating Profit: 27.3 billion yen
- Although the Safety business was affected by the reduction in automobile production, profits exceeded
 the forecasts due mainly to increased sales volume and rising product market prices in Materials,
 Engineering Plastics, and Medical/Healthcare.

♦ 2022/3 Full-year Forecasts

- Sales Revenue: 448 billion yen, Operating Profit: 38 billion yen
- We have upwardly revised our consolidated earnings forecast for the full fiscal year, based on the operating results for the first half of the current consolidated period, exchange rate, demand forecast and procurement prices of raw materials.
- Changes in the commercial operating period of large-scale investment equipment: Carbon monoxide (Acetic acid raw material) Plant and 1,3-BG (Cosmetic ingredients) Plant.
- We will aggressively reduce the assets of low-profit businesses and sell cross-holding of shares with the aim for improving ROIC(return on invested capital.) We incorporate extraordinary profit and loss expected from these efforts into our forecasts.

• Decided to purchase treasury stock of 5 billion yen for 6 million shares. (From Nov. 2021 to Mar 2022)





Trends in Main Markets in 1st Half and Outlook for 2nd Half

Markets	Main businesses Segments	Results of 22/3 1H	Outlook for 22/3 2H
Automotive	Safety Materials Engineering Plastics	Automobile production fell below plan in the first half due to semiconductor shortages and Covid-19	Automobile production is expected to fall below the plan until the third quarter due to the impact of semiconductor shortages and Covid-19, and to recover in the fourth quarter
Semiconductor / Electronic Devices	Smart Materials Engineering Plastics	Semiconductor market grows due to strong demand. Increase in demand for electronic devices such as LCD panels. Increase in demand for base stations and data center along with expansion of 5G network.	Production adjustment is expected for LCD panels because of decline in stay-at-home consumption. High levels of demand for other electronic devices and semiconductors are expected to continue.
Cosmetics / Healthcare	Medical / Healthcare	Domestic cosmetics market has remained sluggish. On the other hand, demand in China recovered early from Covid-19. Domestic health food market has remained strong due to rising health consciousness during Covid-19	Domestic cosmetics market is expected to remain sluggish, and China's demand is expected to grow. Domestic health food market is expected to remain strong





Financial Results

		22 (2 4) 1	22/3 1H Results	YoY		vs For	vs Forecasts	
	21/3 1H Results	22/3 1H Forecasts*		Change	%	Change	%	
Net Sales	175.3	222.0	224.8	+49.5	+28.2%	+2.8	+1.3%	
Operating Income	9.1	23.0	27.3	+18.2	+199.3%	+4.3	+18.5%	
Ordinary Income	10.2	24.0	29.8	+19.7	+193.5%	+5.8	+24.3%	
Income Attributable to Owners of Parent	3.3	16.0	22.0	+18.8	+573.6%	+6.0	+37.8%	
Exchange Rate USD/JPY	107	107	110					

^{*} The forecasts were announced on August 3, 2021.





Financial Results

<Y o Y>

- Demand recovered in a wide range of industries compared to the same period of the previous year, which was greatly affected by Covid-19. Therefore, Sales volume increased mainly for Safety and Engineering Plastics. For Engineering Plastics, the increase in COC production capacity in July also contributed to the increase in sales volume.
- Operating profits increased due to price corrections associated with rising raw material and fuel prices
 and improved profitability through structural reforms, although direct sales costs increased due to an
 increase in sales volume, a global shortage of containers under Covid-19, and soaring transportation
 costs due to rising fuel prices.
- Increases in net income attributable to owners of parent was partly due to the acquisition of Polyplastics as a wholly owned subsidiary in October 2020.

- Sales volume in Safety fell below forecasts due to reduced automobile production, but Medical / Healthcare sales volume exceeds Forecasts.
- Acetic acid market conditions exceeded the plan, boosting profits in Materials.
- Sales prices of Engineering Plastics strongly corrected due to rising raw material prices, centered on POM and PBT, and profits exceeded forecasts.





Net Sales and Operating Income by Segment

Net Sales	21/3 1H	22/3 1H	22/3 1H 22/3 1H		YoY		vs Forecasts	
	Results	Forecasts*	Results	Change	%	Change	%	
Medical / Healthcare	7.8	9.5	9.6	+1.9	+23.8%	+0.1	+1.4%	
Smart	10.3	15.5	15.4	+5.1	+49.7%	-0.1	-0.4%	
Safety	27.2	35.0	31.9	+4.7	+17.3%	-3.1	-8.9%	
Materials	49.3	55.5	58.0	+8.8	+17.8%	+2.5	+4.6%	
Engineering Plastics	74.7	101.0	104.4	+29.7	+39.8%	+3.4	+3.4%	
Others	6.1	5.5	5.4	-0.7	-11.5%	-0.1	-1.8%	
Total	175.3	222.0	224.8	+49.5	+28.2%	+2.8	+1.3%	

Operating Income	21/3 1H	22/3 1H	22/3 1H 22/3 1H	YoY		vs Forecasts	
	Results	Forecasts*	Results	Change	%	Change	%
Medical / Healthcare	0.8	1.6	1.9	+1.1	+132.4%	+0.3	+18.5%
Smart	1.0	3.5	3.4	+2.4	+228.4%	-0.1	-2.8%
Safety	-1.7	3.0	2.4	+4.1	_	-0.6	-20.1%
Materials	7.5	10.5	11.6	+4.2	+55.6%	+1.1	+10.9%
Engineering Plastics	8.2	12.5	15.1	+6.9	+83.6%	+2.6	+20.9%
Others	0.9	0.8	0.8	-0.2	-19.2%	-0.0	-5.5%
Corporate	-7.7	-8.9	-7.9	-0.2	-2.8%	+1.0	+10.7%
Total	9.1	23.0	27.3	+18.2	+199.3%	+4.3	+18.5%

^{*} The forecasts were announced on August 3, 2021.





Net Sales and Operating Income by Segment (Y on Y Analysis)

Net Sales	21/3 1H 22/3 1H		Change 9/		Analysis			
	Results	Results	Change	%	Quantity	Prices	Exchange Rate Impact	
Medical / Healthcare	7.8	9.6	+1.9	+23.8%	+1.9	-0.0	+0.2	
Smart	10.3	15.4	+5.1	+49.7%	+4.3	+0.8	+0.0	
Safety	27.2	31.9	+4.7	+17.3%	+3.3	+1.4	+0.6	
Materials	49.3	58.0	+8.8	+17.8%	+0.9	+7.9	+0.9	
Engineering Plastics	74.7	104.4	+29.7	+39.8%	+19.4	+10.3	+1.6	
Others	6.1	5.4	-0.7	-11.5%	-0.7	-	-	
Total	175.3	224.8	+49.5	+28.2%	+29.1	+20.4	+3.3	

Operating Income	21/3 1H	22/3 1H			Analysis			
Operating income	Results	Results	Change	%	Quantity	Prices	Exchange Rate Impact	Others
Medical / Healthcare	0.8	1.9	+1.1	+132.4%	+1.4	-0.4	+0.1	+0.0
Smart	1.0	3.4	+2.4	+228.4%	+2.3	+0.2	-0.0	-0.1
Safety	-1.7	2.4	+4.1	-	+3.2	+0.7	+0.1	+0.2
Materials	7.5	11.6	+4.2	+55.6%	+0.7	+2.8	+0.5	+0.6
Engineering Plastics	8.2	15.1	+6.9	+83.6%	+8.5	+2.0	+0.6	-3.6
Others	0.9	0.8	-0.2	-19.2%	-0.2	-	-	_
Corporate	-7.7	-7.9	-0.2	-2.8%	-	-	-	-0.2
Total	9.1	27.3	+18.2	+199.3%	+16.0	+5.4	+1.2	-3.2

^{*}Exchange rate impact is included in price impact.





Consolidated Balance Sheet

(billion yen)

	Mar. 31, 2021	Sep. 30, 2021	Change
Total Current Assets	312.5	323.3	+10.8
Cash, Deposits and Short- term Investment Securities	91.5	91.9	+0.4
Notes and Accounts Receivable-trade	93.2	87.4	-5.8
Inventories	108.7	123.5	+14.9
Other	19.2	20.5	+1.4
Total Non-Current Assets	327.9	350.7	+22.8
Property, Plant and Equipment	219.7	223.4	+3.6
Intangible Fixed Assets	10.6	11.5	+0.9
Investments and Other Assets	97.5	115.8	+18.3
Total Assets	640.4	674.0	+33.6
Liabilities	395.4	399.7	+4.3
Interest-bearing Liabilities	270.9	269.8	-1.1
Other	124.4	129.9	+5.4
Total Net Assets	245.0	274.3	+29.3
Total Liabilities and Net Assets	640.4	674.0	+33.6

As of September 30, 2021, total assets increased JPY 33.6 billion compared to March 31, 2021.

- Inventory
 - Build up inventories of engineering plastics, which had been decreasing due to increased demand from the recovery of COVID-19.
 - Inventory unit price has risen due to the impact of rising raw material and fuel prices
- Major project of Capital investment

 Establishment of new production
 - Establishment of new production site for automobile airbag inflators in India.
 - Expanding production capacities for engineering plastic (COC) in Germany.
- Increase in market value of crossshareholdings.





Consolidated Cash Flow Statement

(billion yen)

				,
		2021/3 1H	2022/3 1H	Change
	Cash Flows from Operating Activities	21.9	28.4	+6.6
	Cash Flows from Investing Activities	-18.1	-21.3	-3.2
Free C	ash Flows	3.7	7.1	+3.4
Cash Flows from Financing Activities		-4.3	-7.5	-3.2
Other		0.2	0.5	+0.3
Net In Equiva	crease (Decrease) in Cash and Cash alents	-0.4	0.1	+0.5
resulti	se in cash and cash equivalents ng from inclusion sidiaries in consolidation	-	0.1	+0.1
Cash a	and Cash Equivalents at End of	80.2	90.9	+10.7

During the first half of the current fiscal year under review, free cash flow increased by 3.4 billion yen year-on-year, mainly due to an increase in profits.

Free cash flow was allocated to shareholder returns and borrowing repayments. Therefore, balance of cash and deposits remained at the level at the end of the previous fiscal year, and we have secured a financial base to prepare for sudden changes in the business environment.





Full- year Forecasts


	21/3	22/3	2/3 22/3		YoY		vs Forecasts	
	Results	Forecasts*	Revised Forecasts	Change	%	Change	%	
Net Sales	393.6	435.0	448.0	+54.4	+13.8%	+13.0	+3.0%	
Operating Income	31.7	35.0	38.0	+6.3	+19.8%	+3.0	+8.6%	
Ordinary Income	34.7	37.0	42.0	+7.3	+21.1%	+5.0	+13.5%	
Income Attributable to Owners of Parent	19.7	24.0	24.0	+4.3	+21.7%	-	-	
Exchange Rate USD/JPY	106	106	110					
ROIC	4.1%	4.4%	4.8%					
EBITDA	586	677	662					

^{*} The forecasts were announced on August 3, 2021.





Revised Forecasts - Operating Income (vs Forecasts Analysis)



- Although sales volume of Safety has been revised downward due to the impact of reduced automobile production, sales volume of Engineering Plastics has increased.
- Revise sales prices based on market conditions and promote price corrections due to rising raw material and fuel prices
- Change in foreign exchange assumptions in 2nd half
 - $$\downarrow 105/US$ \Rightarrow $\downarrow 110/US$$ (Full year: \$\pm 106/US\$ \Rightarrow \$\pm 110/US\$)
- Direct selling expenses are expected to increase because of rising transportation costs due to global container shortage and rising fuel prices.
- Depreciation expenses are expected to decrease by 4.5 billion yen due to changes in the commercial operating period of large-scale investment equipment.
 - Carbon monoxide (Acetic acid raw material) Plant Dec. 2021 ⇒ Jun. 2022
 - > 1,3-BG (Cosmetic ingredients) Plant

Jan. $2022 \Rightarrow Jul. 2022$





Progress of Large-scale Investment Project

Renewal of carbon monoxide (acetic acid raw material) plant in Aboshi

- ➤ We reviewed the start of commercial operations from December 2021 to June 2022 after annual maintenance.
- ➤ Tight global acetic acid supply is expected to continue. We reviewed the start of commercial operations of new plant and prioritize the operations of existing plant to fulfill our supply responsibilities.

New 1,3-BG manufacturing plant in Aboshi

- ➤ We found an equipment malfunction during the commissioning period. We plan to resolve this problem during annual maintenance period and start commercial operations in July (previous plan: start commercial operations in January 2022).
- ➤ We are considering the possibility of recovering the investment amount in light of the deterioration of the product market environment due to Covid-19 and the current trend of raw material and fuel costs.





Forecasts - Net Sales and Operating Income by Segment

Net Sales	21/3 22/3		22/3	Υc	Y	vs Forecasts	
	Results	Forecasts	Revised Forecasts	Change	%	Change	%
Medical / Healthcare	16.2	19.0	19.0	+2.8	+17.2%	-	-
Smart	24.7	28.0	30.0	+5.3	+21.5%	+2.0	+7.1%
Safety	67.2	73.5	69.0	+1.8	+2.7%	-4.5	-6.1%
Materials	104.2	108.5	116.0	+11.8	+11.3%	+7.5	+6.9%
Engineering Plastics	168.6	195.0	203.0	+34.4	+20.4%	+8.0	+4.1%
Others	12.7	11.0	11.0	-1.7	-13.2%	-	-
Total	393.6	435.0	448.0	+54.4	+13.8%	+13.0	+3.0%

Operating Income	21/3	22/3	22/3	Υc	YoY		vs Forecasts	
	Results	Forecasts	Revised Forecasts	Change	%	Change	%	
Medical / Healthcare	1.6	2.3	2.7	+1.1	+73.0%	+0.4	+17.4%	
Smart	3.4	4.2	4.2	+0.8	+23.1%	_	-	
Safety	2.2	6.5	5.0	+2.8	+124.1%	-1.5	-23.1%	
Materials	17.9	14.0	19.0	+1.1	+6.0%	+5.0	+35.7%	
Engineering Plastics	21.2	23.0	21.5	+0.3	+1.5%	-1.5	-6.5%	
Others	1.5	1.6	1.6	+0.1	+8.0%	_	_	
Corporate	-16.1	-16.6	-16.0	+0.1	+0.4%	+0.6	+3.6%	
Total	31.7	35.0	38.0	+6.3	+19.8%	+3.0	+8.6%	

^{*} The forecasts were announced on August 3, 2021.





Return to Shareholders

Policy: Maintain the 32 yen per share as the lower limit and total return ration of 40% or higher

FY ending March 2022

- Dividend forecast Interim dividends: 16 yen per share (as expected)
 Forecast of Annual dividends: 32 yen per share
- Decided to purchase treasury stock of 5 billion yen for 6 million shares. (Period of purchase: From Nov. 2021 to Mar. 2022)







Expand profits by turning Polyplastics a wholly owned subsidiary Increased capacity of LCP and POM resins

♦ Construction of a new LCP (Liquid Crystal Polymer) polymerization plant

Polyplastics will construct a new LCP polymerization plant with an annual production capacity of 5,000 tons at Polyplastics Taiwan Co., Ltd. in Taiwan (scheduled to start operation in the first half of 2024).

Demand for LCP has been increasing in recent years due to an increase in investment in 5G equipment, and it is expected that the use of LCP will continue to expand with the full-scale support for 5G. In the future, due to the expansion of the plant in Taiwan, we will increase the annual production to 25,000 tons, including the Fuji plant in Japan (annual production of 15,000 tons).

♦ Advance the timing of increasing POM (polyacetal resin) production

Polyplastics plans to change the timing of POM production increase (annual production of 90,000 tons) planned for 2025 in the Mid-Term Management Strategy, and to build a new plant in Nantong, China (South District) with the start of operations in 2024.

This plan has been advanced due to China's environmental policy requesting the relocation of the current plant (60,000 tons per year) in the city (North District), and negotiations are underway with the authorities regarding the construction of an alternative plant.

With this expansion, the annual production capacity of POM in China will be 150,000 tons, with which we will meet the demand of the growing Chinese market.





Expand sales of sustainable products through customer-in type business CELBLEN EC, Biomass plastic derived from wood and cotton that returns to nature



CELBLEN EC® (cellulose acetate resin)

Non-edible plant-derived, biodegradable biomass plastic

CELBLEN EC combines high environmental properties with processability.

- ✓ Material recyclable & biodegradable, thus contributing to solving the problem of marine plastic pollution.
- ✓ Derived from non-edible plants such as pulp (unlike PLA resin derived from corn), so will not affect any future food supply problems.
- ✓ Achieves moldability equivalent to that of conventional commodity plastic through development of appropriate formulations and realizes high moldability that enable use of existing customer manufacturing facilities.

Future Prospects

- ✓ With its high transparency not found in other biomass plastics, we will focus on adoption in the high-volume food industry. Currently, marketing to distributors is underway.
- ✓ We will establish the technology and a track record of adoption in Japan, where the level of quality requirements is high, and proceed with global expansion into the European and American markets, where the substitution of biodegradable plastics is accelerating.



Build a circular economy and achieving carbon neutrality Joint research and development on a Revolutionary Desktop Chemical Plant

National Tsing Hua University (NTHU, located in Hsinchu City, Taiwan) and Daicel have established the Daicel-NTHU Research Center and started joint research and development on a Revolutionary Desktop Chemical Plant.

Until now, Daicel has committed itself to production transformation and process innovation in order to conserve energy. However, building a circular economy and achieving carbon neutrality demands greater efforts, which has inspired Daicel to pursue the utmost in efficient production technology through development of the Revolutionary Desktop Chemical Plant.

Press release: https://www.daicel.com/en/news/assets/pdf/20211028_3.pdf

Parallelization

Image courtesy
Institute of Microchemical Technology Co., Ltd.

Microfluidic System

A microfluidic system allows the mixing and extracting

<u>Desktop Chemical Plant</u> (Image of proposed experimental plant)

operations with a glass chip the size of a business card.






Build a circular economy and achieving carbon neutrality Comprehensive collaboration agreement with Kyoto University

Daicel has concluded a comprehensive collaboration agreement with Kyoto University to contribute to the regeneration of forests, rivers, the sea and local cities, the realization of a low-carbon society that coexists with nature and the creation of new industries, etc. by effectively utilizing biomass such as wood, agricultural and fishery waste.

In addition, for the purpose of realization of "New Biomass Product Tree", based on this agreement, Daicel has concluded a comprehensive research collaboration agreement with Research Institute for Sustainable Humanosphere, Institute for Chemical Research, Institute of Advanced Energy, Graduate School of Agriculture and Graduate School of Human and Environmental Studies. Then, Daicel has established "Biomass Product Tree industry-Academia Collaborative Research Laboratory" as a base for industry-academia collaborative research in

the Kyoto University Uji campus.








REFERENCES



Trend in Net Sales and Operating Income and Forecasts







Segment Information – Results of 2nd Quarter (Jul. to Sep.)

Medical /	 Sales volume of 1,3-BG (Cosmetic ingredients) exceeded the plan in the Chinese market.
Healthcare	 Overseas sales volume of chiral column and stationary phases exceeded the plan in Chiral separation business.
Smart	 Sales volume of cellulose acetate for LCD films was almost as planned. Sales revenue of high performance films decreased because of decrease in sales volume for automobiles due to the impact of reduced automobile production.
	 Full production of solvents for electronic materials and resist materials continued. Sales of solvents for electronic materials increased from the plan due to the promotion of price correction accompanying the rise in raw material prices. Sales volume of resist materials increased from plan due to new products in addition to increases in existing products.
Safety	Inflator sales volume decreased from plan due to decreases in automobile production because of semiconductor shortages and Covid-19.





Segment Information – Results of 2nd Quarter (Jul. to Sep.)

Materials	Market conditions for acetic acid were higher than expected. Along with this, sales price of acetic acid derivative also increased more than planned.
	 Sales volume of acetate tow increased from the plan due to recovery of demand mainly in Asia and securing of inventory by customers.
	 Sales revenue of caprolactone derivatives and epoxy compounds exceeded the plan due to increase in sales volume and sales price revisions along with raw material price increases.
Engineering Plastics	 Sales volume decreased from the plan due to the adverse impact of Covid- 19 on the operation of the Malaysian Plant. Limited effect from decline in automobile production due to semiconductor shortage.
	 Sales increased more than planned due to correction of selling prices due to rising raw material prices and the impact of exchange rates.





Segment Information - Outlook for 2nd Half (Oct. to Mar.)

	Medical /	 New 1.3-BG plant at Aboshi will start commercial operation from Jul. 2022 (Previous plan: Start from Jan. 2022) 					
Healthcare	Healthcare	 Sales of chiral columns and stationary phases are expected to exceed the plan due to increased demand in overseas markets centered on China. 					
	Smart	 Demand for cellulose acetate for LCD films is expected to remain above the plan, although production adjustments of LCD panels are expected in the second half of the year. Sales volume of high performance films is expected to increase due to new adoption for the surface of TV displays and acquisition of new overseas users. 					
		 Full production of solvents for electronic materials and resist materials will continue. Sales of solvents for electronic materials are expected to exceed the plan due to sales expansion and price corrections due to rising raw material prices. 					
		 In the sensing business, sales plans are not expected to be achieved, as some new projects have been postponed due to a shortage of semiconductors. On the other hand, new customer inquiries such as lenses for AR / VR are increasing, and we will actively develop new projects. 					





Segment Information - Outlook for 2nd Half (Oct. to Mar.)

Safety	 Inflator sales volume is expected to be lower than planned due to the impact of lower automobile production 					
	 Accumulate cost reductions such as direct labor costs and other expenses in line with operational reductions 					
Materials	 Acetic acid market has risen due to Chinese environmental regulations. Therefore, we revised our acetic acid market price assumption. 					
	 In order to achieve a stable supply of acetic acid, the start of commercial operations of the carbon monoxide (acetic acid raw material) plant was revised to June 2022 (Previous plan: Start from Dec. 2021) 					
	 Manufacturing costs for chemical products will rise due to rising raw material and fuel prices, but we will actively promote price corrections to respond. 					
	 The 2022 annual contract price of acetate tow with major customers is expected to be about the same as the previous year as planned. However Increased direct selling expenses will cause a decrease in profits. 					





Segment Information - Outlook for 2nd Half (Oct. to Mar.)

<vs Forecasts>

Engineering Plastics

- Although full production of POM, PBT, PPS, and LCP will continue, the sales volume is expected to decrease from the plan except for LCP by adjusting sales because the inventory remains tight. COC is expected to fall below plan due to postponement of large-scale development projects by customers due to Covid-19.
- Raw material prices exceed plan, however we will strongly promote price correction
- Direct selling expenses are expected to exceed the plan due to rising transportation costs and special transportation in the second half





Quarterly Results for Sales and Operating income

Net Sales		202	1/3	/3 2022/3				
iver sales	1 st Quarter	2 nd Quarter	3 rd Quarter	4 th Quarter	1 st Quarter	2 nd Quarter		
Medical / Healthcare	3.9	3.9	4.2	4.2	4.8	4.8		
Smart	5.1	5.2	7.3	7.1	8.0	7.5		
Safety	10.7	16.5	19.5	20.5	16.3	15.6		
Materials	25.6	23.7	25.6	29.3	28.3	29.8		
Engineering Plastics	35.2	39.5	46.5	47.4	51.5	52.9		
Others	2.4	3.7	3.0	3.6	2.6	2.8		
Total	82.9	92.4	106.0	112.2	111.4	113.5		


Operating income		2021/3 2022/3				
Operating income	1 st Quarter	2 nd Quarter	3 rd Quarter	4 th Quarter	1 st Quarter	2 nd Quarter
Medical / Healthcare	0.4	0.4	0.4	0.3	0.9	1.0
Smart	0.6	0.4	1.0	1.3	2.0	1.4
Safety	-2.3	0.6	2.2	1.7	0.7	1.7
Materials	3.9	3.6	3.4	7.1	6.0	5.6
Engineering Plastics	3.9	4.3	5.8	7.1	8.2	6.9
Others	0.4	0.5	0.4	0.2	0.5	0.2
Corporate	-3.8	-3.9	-3.6	-4.7	-4.4	-3.6
Total	3.1	6.0	9.6	13.0	13.9	13.3





Capital Expenditures











Depreciation and Amortization







R&D







Financial Forecast (FY ending March 2022)

	2022/3 Previous Forecasts 2022/3 Revised Forecasts			ecasts	Change		
	1 st Half	2 nd Half	Total(A)	1 st Half	2 nd Half	Total(B)	(B)-(A)
Medical / Healthcare	9.5	9.5	19.0	9.6	9.4	19.0	-
Smart	15.5	12.5	28.0	15.4	14.6	30.0	+2.0
Safety	35.0	38.5	73.5	31.9	37.1	69.0	-4.5
Materials	55.5	53.0	108.5	58.0	58.0	116.0	+7.5
Engineering Plastics	101.0	94.0	195.0	104.4	98.6	203.0	+8.0
Others	5.5	5.5	11.0	5.4	5.6	11.0	-
Net sales	222.0	213.0	435.0	224.8	223.2	448.0	+13.0
Medical / Healthcare	1.6	0.7	2.3	1.9	8.0	2.7	+0.4
Smart	3.5	0.7	4.2	3.4	0.8	4.2	-
Safety	3.0	3.5	6.5	2.4	2.6	5.0	-1.5
Materials	10.5	3.5	14.0	11.6	7.4	19.0	+5.0
Engineering Plastics	12.5	10.5	23.0	15.1	6.4	21.5	-1.5
Others	0.8	0.8	1.6	0.8	0.8	1.6	-
Corporate	-8.9	-7.7	-16.6	-7.9	-8.1	-16.0	+0.6
Operating income	23.0	12.0	35.0	27.3	10.7	38.0	+3.0
Ordinary income	24.0	13.0	37.0	29.8	12.2	42.0	+5.0
Income attributable to owners of parent	16.0	8.0	24.0	22.0	2.0	24.0	-
(ref.) Exchange rate USD/JPY	107	105	106	110	110	110	

^{*} The forecasts were announced on August 3, 2021.





Assumptions

		202 Res		2022/3 Results & Previous Forecasts		2022/3 Results & Revised Forecasts		
		1 st Half (Results)	2 nd Half (Results)	1 st Quarter (Results)	2 nd Quarter (Forecasts)	2 nd Half (Forecasts)	1 st Half (results)	2 nd Half (Forecasts)
Exchange rate (USD/JPY)		107	105	110	105	105	110	110
	Methanol Asian spot price (USD/ton)	192	316	357	340	340	377	500
Raw Materials	Crude Oil Dubai (USD/bbl.)	37	53	67	70	70	70	85
	Domestic Naphtha (JPY/kl)	27,500	34,500	48,000	48,000	48,000	50,350	60,000






Newly Released Annual Report "DAICEL REPORT 2021"

"DAICEL REPORT 2021" English version released in October.

This report includes financial and non-financial information to explain to our stakeholders the path to improving our corporate value.



Main Points

- ✓ Explanation of Long-Term Vision and Mid-Term Management Strategy
- ✓ Identifies Key Sustainability Issues (Materiality)
- ✓ Expands information disclosure on sustainable procurement
- ✓ Reports on roundtable discussion with Outside Directors

To read PDF version, or to know more details about our ESG initiatives, please visit our website. https://www.daicel.com/en/sustainability/

Notes Regarding Forward-Looking Statements



- The purpose of this document is to provide information and not to persuade any individual to take any action in response to the information contained in this document. Daicel has made the greatest possible effort to prepare this document with accurate information. The information in this document, however, may include risks or inaccuracy, and we do not guarantee the accuracy or reliability of this information.
- The reader is advised that the use of the information in this document is at your own risk. Any investment according to the prospects, target values, etc. appearing in this document might result in a loss. Daicel accepts no responsibility for such an eventuality.

All rights reserved by Daicel Corporation.

This document shall not be copied or distributed to a third party without the permission of Daicel Corporation.